Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of parkinson disease and evidence of interaction effects

JAMA Neurology

Volumn 72, Issue 2, 2015, Pages 194-200

  Bohnen, Nicolaas I ^a,b   Albin, Roger L ^a,b,c   Müller, Martijn L T M ^a   Petrou, Myria ^a   Kotagal, Vikas ^a   Koeppe, Robert A ^a   Scott, Peter J H ^a   Frey, Kirk A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROTETRABENAZINE C 11; METHYL 4 PIPERIDINYL PROPIONATE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ACETYLCHOLINE; DOPAMINE;

AGED; ARTICLE; BRAIN CORTEX; CAUDATE NUCLEUS; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DEMENTIA; DENERVATION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOCORTEX; NERVE DEGENERATION; NEUROIMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; CHOLINERGIC NERVE CELL; COGNITION DISORDERS; COMPLICATION; DOPAMINERGIC NERVE CELL; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ACETYLCHOLINE; AGED; CAUDATE NUCLEUS; CEREBRAL CORTEX; CHOLINERGIC NEURONS; COGNITION DISORDERS; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX;

EID: 84923012194     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.2757     Document Type: Article

References (34)

1. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain. 2007;130(pt 7):1787-1798.
2. Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11(2):79-92.
3. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74(11):885-892.
4. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60(12):1745-1748.
5. Bohnen NI, Müller ML, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab. 2012;32(8):1609-1617.
6. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 1996;40(6): 873-884.
7. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26(9):1198-1212.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
9. Goetz CG, Poewe W, Rascol O, et al; Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020-1028.
10. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41-47.
11. Aarsland D, Brønnick K, Larsen JP, Tysnes OB, Alves G; Norwegian ParkWest Study Group. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology. 2009;72(13):1121-1126.
12. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test Manual, Adult Version. 2nd ed. San Antonio, TX: The Psychological Corporation; 2000.
13. Wechsler D. WAIS III Technical Manual. San Antonio, TX: The Psychological Corporation; 1997.
14. Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System (D-KEFS): Examiner's Manual. San Antonio, TX: The Psychological Corporation; 2001.
15. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643-662.
16. Benton AL, Varney NR, Hamsher K. Judgment of Line Orientation, Form V. Iowa City: University of Iowa Hopsitals; 1975.
17. Shao X, Hoareau R, Hockley BG, et al. Highlighting the versatility of the Tracerlab synthesis modules, part 1: fully automated production of [F]labelled radiopharmaceuticals using a Tracerlab FX(FN). J Labelled Comp Radiopharm. 2011;54(6):292-307.
18. 11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab. 1997;17(9):919-931.
19. 11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. J Cereb Blood Flow Metab. 2001;21(11):1354-1366.
20. Logan J, Fowler JS, Volkow ND, Ding YS, Wang GJ, Alexoff DL. A strategy for removing the bias in the graphical analysis method. J Cereb Blood Flow Metab. 2001;21(3):307-320.
21. Bohnen NI, Müller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73 (20):1670-1676.
22. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol. 1996;40(3):399-410.
23. Shinotoh H, Namba H, Yamaguchi M, et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol. 1999;46(1):62-69.
24. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65 (11):1716-1722.
25. Ruberg M, Rieger F, Villageois A, Bonnet AM, Agid Y. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease. Brain Res. 1986;362(1):83-91.
26. Choi SH, Jung TM, Lee JE, Lee SK, Sohn YH, Lee PH. Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status. Neurobiol Aging. 2012;33(7):1265-1272.
27. Kucinski A, Paolone G, Bradshaw M, Albin RL, Sarter M. Modeling fall propensity in Parkinson's disease: deficits in the attentional control of complex movements in rats with cortical-cholinergic and striatal-dopaminergic deafferentation. J Neurosci. 2013;33(42):16522-16539.
28. Sarter M, Albin RL, Kucinski A, Lustig C. Where attention falls: increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. Exp Neurol. 2014;257:120-129.
29. Bohnen NI, Frey KA, Studenski S, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology. 2013;81(18): 1611-1616.
30. van Schouwenburg MR, O'Shea J, Mars RB, Rushworth MF, Cools R. Controlling human striatal cognitive function via the frontal cortex. J Neurosci. 2012;32(16):5631-5637.
31. Calabresi P, Picconi B, Parnetti L, Di Filippo M. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol. 2006;5(11):974-983.
32. Petrou M, Frey KA, Kilbourn MR, et al. In vivo imaging of human cholinergic nerve terminals with (-)-5-(18)F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses. J Nucl Med. 2014;55(3):396-404.
33. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, Guerra MJ, Lanciego JL, Labandeira-Garcia JL. Estrogen and angiotensin interaction in the substantia nigra: relevance to postmenopausal Parkinson's disease. Exp Neurol. 2010;224(2): 517-526.
34. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord. 2014;29(5):634-650.